Latest / The Well-Built Life / Breaking Through: Immuno-Oncology’s Next Frontier
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:21Speaker 1: and let's dive in. Welcome to The Well-Built Life, where
- 0:24Speaker 1: we dive into the latest advancements in health and wellness, Today,
- 0:28Speaker 1: we are breaking down a fascinating breakthrough, Febstery, an experimental
- 0:33Speaker 1: drug that's making waves in the field of oncology.
- 0:36Speaker 2: Right, and that's the crucial nuance here. Febstery addresses a
- 0:40Speaker 2: major challenge in treating solid tumors by tackling the tumor
- 0:43Speaker 2: barrier composed of TGF1-induced fibrous tissue.
- 0:47Speaker 1: Exactly, which brings up an interesting contradiction. On the surface,
- 0:52Speaker 1: it looks straightforward. The drug targets TGFY to weaken the
- 0:56Speaker 1: tumor's protective shield. But when you dig into the mechanics,
- 1:00Speaker 1: the incentive to suppress TGF, systemically, has failed in clinical trials.
- 1:05Speaker 2: That's wild when you look at the raw numbers. In
- 1:08Speaker 2: aggressive pancreatic tumors, FEP, Strachry cleared the tumor in 75%
- 1:14Speaker 2: of treated mice with up to 270 days of survival post. Treatment.
- 1:20Speaker 2: It's a stark comparison to the systemic failure. Right.
- 1:24Speaker 1: It's all about the targeted approach. By attaching a modified
- 1:28Speaker 1: form of the drug to fibronectin, it selectively concentrates in
- 1:32Speaker 1: the tumor site where TGFY activity is localized and suppressed.
- 1:38Speaker 1: Once the barrier is down, infiltrating T cells can release
- 1:41Speaker 1: interferon gamma, converting support cells into immune allies.
- 1:46Speaker 2: And this change in the tumor microenvironment is profound. The
- 1:50Speaker 2: drug altered the activity of 693 genes in the blood
- 1:54Speaker 2: compared to just 25 with non-targeted methods. It's a game changer.
- 1:59Speaker 1: Absolutely. But it's not without its challenges. There are latent contradictions,
- 2:05Speaker 1: especially in the variable immune response. The generalizability of these
- 2:10Speaker 1: results from mice to humans is still a critical point
- 2:13Speaker 1: of debate.
- 2:14Speaker 2: True. And that's why moving from preclinical to clinical trials
- 2:18Speaker 2: is so complex. Ensuring the drug can be manufactured at
- 2:21Speaker 2: scale without losing its efficacy is a major challenge.
- 2:25Speaker 1: Definitely. What's intriguing is the potential for this drug to
- 2:29Speaker 1: be tailored to other solid tumor types, particularly those with
- 2:33Speaker 1: varying TGF-UZ expression profiles. The future outlook is promising, but
- 2:39Speaker 1: it's going to take collaboration between academic and industrial researchers
- 2:43Speaker 1: to make it a reality.
- 2:45Speaker 2: Yes, and with clinical trials slated for 2027, We are
- 2:49Speaker 2: on the cusp of a new era in cancer treatment.
- 2:53Speaker 2: This drug could open the door for comprehensive cancer protection,
- 2:57Speaker 2: potentially revolutionizing the landscape of solid tumor management.
- 3:01Speaker 1: Let's break down how this drug works on a deeper level.
- 3:05Speaker 1: It's targeting TGF1I, but that's a signaling molecule with a
- 3:09Speaker 1: complex role in cancer. So, how exactly is it being targeted,
- 3:15Speaker 1: and what's the rationale behind that approach? Exactly.
- 3:18Speaker 2: TGF-Fi has a double-edged sword effect promoting tumor growth and
- 3:22Speaker 2: suppressing immune responses. By attaching the drug to fibronectin, which
- 3:27Speaker 2: is highly present in tumors but not in healthy tissues,
- 3:31Speaker 2: the drug can selectively target the tumor site, thereby weakening
- 3:34Speaker 2: the tumor's protective barrier. This localized strategy avoids disrupting healthy tissues.
- 3:40Speaker 1: Right. This selective delivery system is the key. It ensures
- 3:45Speaker 1: that the drug only acts in the tumor microenvironment, reducing
- 3:49Speaker 1: the risk of systemic side effects. It's a smart design,
- 3:53Speaker 1: but what happens next? How does it trigger an immune response?
- 3:57Speaker 2: Once TGF1 is suppressed locally, the microenvironment changes, allowing T
- 4:02Speaker 2: cells to infiltrate. These T cells release interferon gamma, which
- 4:07Speaker 2: converts support cells into immune allies. This not only directly
- 4:12Speaker 2: fights the cancer but also establishes long-lasting immune memory. It's
- 4:16Speaker 2: like the drug is laying down a map for the
- 4:18Speaker 2: immune system, teaching it to recognize and respond more effectively
- 4:22Speaker 2: to a recurrence.
- 4:23Speaker 1: That's fascinating. But how does this translate to long-lasting protection
- 4:28Speaker 1: against cancer recurrence? The drug seems to create a lasting effect.
- 4:34Speaker 1: Can you elaborate on that process? Wait. But how does
- 4:37Speaker 1: that actually play out in practice? How do you monitor
- 4:41Speaker 1: and ensure the drug keeps working long-term?
- 4:43Speaker 2: Monitoring long-term efficacy is a bit challenging, but the promising
- 4:47Speaker 2: data from the study show that the drug's effects are
- 4:50Speaker 2: significant and persistent. Clinical trials scheduled for 2027 will closely
- 4:55Speaker 2: watch for adverse effects and whether this long-lasting immunity holds
- 4:59Speaker 2: up in human patients. It's a step forward, but Therese
- 5:03Speaker 2: still much to learn.
- 5:04Speaker 1: That's an intriguing approach. It seems to offer hope for
- 5:07Speaker 1: new treatment strategies in solid tumors. But what are the
- 5:11Speaker 1: key challenges we might face in bringing this to wider use?
- 5:15Speaker 2: Absolutely. One big concern is the variability in TGF1 expression
- 5:20Speaker 2: among different solid tumor types. While the drug shows promise,
- 5:24Speaker 2: we will need to tailor it to specific profiles to
- 5:26Speaker 2: ensure effectiveness. Additionally, moving from preclinical to clinical trials requires
- 5:32Speaker 2: addressing dosing, manufacturing, and scalability issues to ensure the drug
- 5:38Speaker 2: maintains its efficiency at larger scales.
- 5:40Speaker 1: As we delve into the broader applicability of Febster Rea,
- 5:44Speaker 1: let's consider the roles of the various stakeholders involved. Dr.
- 5:48Speaker 1: Sung Jin Kim at MedPacto, Inc. is the principal investigator
- 5:53Speaker 1: leading the charge with his colleagues, but how does this
- 5:55Speaker 1: align with the needs of academic and clinical collaborators, like Dr.
- 6:00Speaker 1: John J. Leterio from the university hospitals? Rainbow Babies, Children's Hospital.
- 6:07Speaker 2: Exactly. Each stakeholder brings unique perspectives. For instance, Medpacto Inc.
- 6:13Speaker 2: Being a private biotech company has a primary focus on
- 6:16Speaker 2: developing the drug for market. On the other hand, Dr. Warr,
- 6:20Speaker 2: Laterio's role at a major teaching hospital means he is
- 6:24Speaker 2: also deeply involved in the translational research, ensuring the drug
- 6:28Speaker 2: can be tested safely and effectively in real-world scenarios. Right.
- 6:33Speaker 1: And this dynamic interplay between academic and industrial stakeholders is crucial.
- 6:39Speaker 1: The Developmental Therapeutics Program at Case Comprehensive Cancer Center and
- 6:44Speaker 1: University Hospitals, Cleveland Medical Center, play a pivotal role in
- 6:48Speaker 1: bridging this gap. Their collaborative efforts not only drive the
- 6:52Speaker 1: science forward, but also help address the challenges of scaling
- 6:56Speaker 1: up production.
- 6:57Speaker 2: True. And this partnership highlights the complexity of translating lab
- 7:01Speaker 2: findings into clinical applications. From a funding perspective, it's unlikely
- 7:06Speaker 2: MIPACTO wouldn't have significant backing from national and international health
- 7:10Speaker 2: research bodies given the comprehensive nature of the study. This
- 7:14Speaker 2: funding is essential for the drug's ongoing clinical trials and
- 7:18Speaker 2: safety testing set for 2027. That's a key point.
- 7:23Speaker 1: The balance between securing these resources and the necessity for
- 7:26Speaker 1: rigorous testing is ever-present. As we look ahead, the upcoming
- 7:31Speaker 1: clinical trials will be crucial in validating Feb's deuterium's safety
- 7:35Speaker 1: and efficacy. Ensuring these trials are ethically sound and properly
- 7:39Speaker 1: controlled will be paramount.
- 7:41Speaker 2: Absolutely. The debates surrounding the drug's efficacy and safety are multifaceted.
- 7:46Speaker 2: The localized suppression of TGFY seems promising. but the variable
- 7:51Speaker 2: immune response across different patient populations raises questions about the
- 7:54Speaker 2: drug's generalizability. We need to see how it performs in
- 7:58Speaker 2: more diverse clinical settings.
- 8:00Speaker 1: And the potential for off-target effects from prolonged drug presence
- 8:03Speaker 1: in the tumor microenvironment is certainly a concern. This ties
- 8:08Speaker 1: into the broader debate about the optimal dosing and manufacturing
- 8:12Speaker 1: processes to ensure efficacy without compromising safety. Balancing these factors
- 8:18Speaker 1: will be key in achieving widespread applicability.
- 8:21Speaker 2: That's well said as we continue to explore FEB Stare.
- 8:26Speaker 2: The interplay between these stakeholders and the critical debates surrounding
- 8:30Speaker 2: its efficacy, safety, and potential broad applicability will shape the
- 8:35Speaker 2: future of cancer treatment.
- 8:37Speaker 1: The upcoming clinical trials for FEB Stare are crucial. They
- 8:41Speaker 1: will need to address several key questions. For instance, understand
- 8:45Speaker 1: the gene expression changes post-treatment is a big one.
- 8:48Speaker 2: Absolutely. These changes could give us insights into the long-term
- 8:52Speaker 2: effects and potential side effects. For example, how do these
- 8:56Speaker 2: changes correlate with the sustained immune response observed in mouse models?
- 9:00Speaker 1: That's the million-dollar question. We know the drug is effective,
- 9:05Speaker 1: but the gene expression shifts could help us predict which
- 9:08Speaker 1: patients might benefit the most and where the risks lie.
- 9:12Speaker 2: And Therese, the challenge of tailoring this therapy to different
- 9:15Speaker 2: solid tumor types. TGF4 expression profiles can vary widely. How
- 9:20Speaker 2: can we make sure Feb-Stiray works across the board? True.
- 9:24Speaker 1: That's going to be a major focus, especially when you
- 9:27Speaker 1: consider the variability in TGF1' s role in different cancers. But
- 9:32Speaker 1: let's not lose sight of the potential for combination therapies.
- 9:35Speaker 1: Pairing Feb-Stiray with other immunotherapies Exactly.
- 9:41Speaker 2: Combining this targeted approach with, say, anti-IPD-1 inhibitors could boost
- 9:47Speaker 2: the immune response even more. It's all about maximizing the
- 9:51Speaker 2: therapeutic window.
- 9:52Speaker 1: That's the idea. But the upcoming trials will also need
- 9:56Speaker 1: to establish the optimal dosing and manufacturing processes. to ensure
- 10:00Speaker 1: both efficacy and safety. It's a delicate balance.
- 10:04Speaker 2: Definitely. And the trials need to be well-designed to gather
- 10:07Speaker 2: enough data to support these claims. Dr. Seongjin Kim's quote
- 10:12Speaker 2: about teaching the immune system lessons, it remembers, stands out.
- 10:16Speaker 2: That's a powerful concept. Yes.
- 10:18Speaker 1: And if we can turn those long-term immune responses into
- 10:21Speaker 1: practical therapeutic strategies, it could revolutionize cancer treatment. The future
- 10:27Speaker 1: looks bright, but, Therese, still a lot to unravel. So,
- 10:31Speaker 1: as we wrap up today, let's look at how this
- 10:34Speaker 1: innovative FEB starvity could change the game for solid tumor treatment.
- 10:38Speaker 1: Just consider the long-term immune response it generates, not only
- 10:42Speaker 1: in cancer types like pancreatic and breast, but potentially across
- 10:46Speaker 1: the board.
- 10:47Speaker 2: Exactly. It's a groundbreaking approach in immuno-oncology, where the key
- 10:51Speaker 2: isn't just about fighting the cancer, but teaching the immune
- 10:54Speaker 2: system to remember and protect in the future. That's what Dr.
- 10:58Speaker 2: Kim was referring to when he talked about lessons the
- 11:01Speaker 2: immune system remembers. Fascinating, right? But how does that tie
- 11:05Speaker 2: into the broader field?
- 11:06Speaker 1: Well, it's a significant shift because traditional treatments, like chemotherapy
- 11:11Speaker 1: and radiation, are often just killing the tumor cells in
- 11:14Speaker 1: the moment, without addressing the underlying issues. This drug seems
- 11:18Speaker 1: to be more of a long-term solution, making it a
- 11:21Speaker 1: revolutionary step forward.
- 11:23Speaker 2: And thinking about the clinical trials coming up, we have
- 11:25Speaker 2: to consider the design of these studies. They will be
- 11:28Speaker 2: crucial in ensuring that the drug is not just effective
- 11:31Speaker 2: for those who can afford it, but safe and accessible
- 11:34Speaker 2: to a larger pool of patients. In this globalized world,
- 11:37Speaker 2: equity in treatment should be a top priority.
- 11:40Speaker 1: Absolutely. The upcoming trials are indeed a double-edged sword. We
- 11:45Speaker 1: need to see if this drug can be both efficacious
- 11:47Speaker 1: and cost-effective. Also, addressing the potential off-target effects, given the
- 11:53Speaker 1: complexity of the immune system, it's important to have a
- 11:56Speaker 1: robust safety profile.
- 11:58Speaker 2: True, but stepping back, this is just another step in
- 12:01Speaker 2: a broader narrative. The history of oncology is rife with
- 12:04Speaker 2: such groundbreaking discoveries that challenge and then re-establish the foundations
- 12:09Speaker 2: of treatment. Feb's story fits into that narrative too, pushing
- 12:12Speaker 2: the boundaries of what we thought possible.
- 12:15Speaker 1: Exactly. It's the culmination of years of research and collaboration.
- 12:19Speaker 1: And as we look to the future, Therese, a lot
- 12:22Speaker 1: of work to be done. Combining this with other therapies,
- 12:26Speaker 1: addressing the gene expression, changes it induces, and navigating the
- 12:30Speaker 1: complex regulatory landscape will all be key.
- 12:33Speaker 2: Yes, and it's exciting. The potential for Febsterie to transform
- 12:38Speaker 2: solid tumor treatment isn't just a mirage. It's already showing
- 12:42Speaker 2: promise in preclinical models and mouse studies. The future looks vibrant,
- 12:46Speaker 2: but Therese still much work ahead to ensure that this
- 12:49Speaker 2: breakthrough translates into real world benefits.
- 12:52Speaker 1: That brings us to the end of today's episode. Thank
- 12:55Speaker 1: you so much for spending part of your day with me.
- 12:58Speaker 1: If you found this episode's tips helpful and want to
- 13:01Speaker 1: make sure you don't miss the next conversation, please take
- 13:04Speaker 1: a quick second to hit that subscribe or follow button
- 13:07Speaker 1: on whatever platform you are listening on. It's a completely
- 13:10Speaker 1: free way to support the show and helps more people
- 13:13Speaker 1: find us. This podcast is independently produced, so if you
- 13:18Speaker 1: are ever in a position where you would like to
- 13:20Speaker 1: help keep it running, we do accept small donations. You
- 13:24Speaker 1: can find a link right in the episode description below
- 13:26Speaker 1: to buy us a coffee or contribute what you can.
- 13:30Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 13:36Speaker 1: and we will talk again soon.